Global Benign Prostatic Hyperplasia (BPH) Drugs Market 2017-2021
出 版 商：Technavio
出版日期：2017/05/10
頁 數：70頁
文件格式：PDF
價 格：
USD 3,500 (Single-User License)
USD 4,000 (Multi-User License)
USD 5,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 5,000 (Global-User License)
ABSTRACT
About Benign Prostatic Hyperplasia Drugs
Urology is a branch of medicine that deals with the health of the urinary tract and reproductive tract in men and women. Urologic diseases or conditions include infection in the urinary tract, bladder control problems, kidney stones and prostate problems, among others. The prostate gland surrounds the urethra, the tube that carries urine from the bladder out of the body. Benign prostatic hyperplasia (BPH) is an enlarged prostate, which increases the size of the prostate gland. As the prostate gets enlarged, it may squeeze or partly block the urethra, resulting in significantly blocking urine flow. BPH is normal in the aging process of a male, caused by changes in hormone balance and cell-growth.
Technavio’s analysts forecast the global benign prostatic hyperplasia drugs market to grow at a CAGR of 7.07% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global benign prostatic hyperplasia drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
‧ Americas
‧ APAC
‧ EMEA
Technavio's report, Global Benign Prostatic Hyperplasia Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
‧ Astellas Pharma
‧ Eli Lilly
‧ GlaxoSmithKline
‧ Sanofi
Other prominent vendors
‧ ADC Therapeutics
‧ Advaxis
‧ Agennix
‧ ANI Pharmaceuticals
‧ Bayer HealthCare
‧ BHR Pharma
‧ Bristol-Myers Squibb
‧ Boehringer Ingelheim
‧ Dendreon (Valeant Pharmaceuticals)
‧ Eisai
‧ Endo Pharmaceuticals
‧ Ferring
‧ Foresee Pharmaceuticals
‧ Io Therapeutics
‧ LIDDS
‧ Madrigal Pharmaceuticals
‧ Merck
‧ Novartis
‧ Nymox Pharmaceutical
‧ Spectrum Pharmaceuticals
‧ Takeda Pharmaceuticals
‧ Teva Pharmaceutical Industries
‧ Urologix
Market driver
‧ Growing geriatric male population.
‧ For a full, detailed list, view our report
Market challenge
‧ Availability of minimally invasive surgery as a drug replacement.
‧ For a full, detailed list, view our report
Market trend
‧ Advancements in early-stage diagnosis through new diagnostic methods.
‧ For a full, detailed list, view our report
Key questions answered in this report
‧ What will the market size be in 2021 and what will the growth rate be?
‧ What are the key market trends?
‧ What is driving this market?
‧ What are the challenges to market growth?
‧ Who are the key vendors in this market space?
‧ What are the market opportunities and threats faced by the key vendors?
‧ What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
About Benign Prostatic Hyperplasia Drugs
Urology is a branch of medicine that deals with the health of the urinary tract and reproductive tract in men and women. Urologic diseases or conditions include infection in the urinary tract, bladder control problems, kidney stones and prostate problems, among others. The prostate gland surrounds the urethra, the tube that carries urine from the bladder out of the body. Benign prostatic hyperplasia (BPH) is an enlarged prostate, which increases the size of the prostate gland. As the prostate gets enlarged, it may squeeze or partly block the urethra, resulting in significantly blocking urine flow. BPH is normal in the aging process of a male, caused by changes in hormone balance and cell-growth.
Technavio’s analysts forecast the global benign prostatic hyperplasia drugs market to grow at a CAGR of 7.07% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global benign prostatic hyperplasia drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
‧ Americas
‧ APAC
‧ EMEA
Technavio's report, Global Benign Prostatic Hyperplasia Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
‧ Astellas Pharma
‧ Eli Lilly
‧ GlaxoSmithKline
‧ Sanofi
Other prominent vendors
‧ ADC Therapeutics
‧ Advaxis
‧ Agennix
‧ ANI Pharmaceuticals
‧ Bayer HealthCare
‧ BHR Pharma
‧ Bristol-Myers Squibb
‧ Boehringer Ingelheim
‧ Dendreon (Valeant Pharmaceuticals)
‧ Eisai
‧ Endo Pharmaceuticals
‧ Ferring
‧ Foresee Pharmaceuticals
‧ Io Therapeutics
‧ LIDDS
‧ Madrigal Pharmaceuticals
‧ Merck
‧ Novartis
‧ Nymox Pharmaceutical
‧ Spectrum Pharmaceuticals
‧ Takeda Pharmaceuticals
‧ Teva Pharmaceutical Industries
‧ Urologix
Market driver
‧ Growing geriatric male population.
‧ For a full, detailed list, view our report
Market challenge
‧ Availability of minimally invasive surgery as a drug replacement.
‧ For a full, detailed list, view our report
Market trend
‧ Advancements in early-stage diagnosis through new diagnostic methods.
‧ For a full, detailed list, view our report
Key questions answered in this report
‧ What will the market size be in 2021 and what will the growth rate be?
‧ What are the key market trends?
‧ What is driving this market?
‧ What are the challenges to market growth?
‧ Who are the key vendors in this market space?
‧ What are the market opportunities and threats faced by the key vendors?
‧ What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
‧ Market outline
PART 05: BPH diagnostics
‧ Overview
PART 06: Pipeline landscape
PART 07: Market landscape
‧ Market overview
‧ Five forces analysis
PART 08: Market segmentation by MOA
‧ Alpha-blockers
‧ 5-ARIs
‧ PDE-5 inhibitors
‧ Others
PART 09: Geographical segmentation
‧ BPH drugs market in Americas
‧ BPH drugs market in EMEA
‧ BPH drugs market in APAC
PART 10: Decision framework
PART 11: Drivers and challenges
‧ Market drivers
‧ Market challenges
PART 12: Market trends
‧ Advancements in early-stage diagnosis through new diagnostic methods
‧ Growing demand for MRI and ultrasound-guided prostate biopsy procedures
‧ Growing focus toward new MOA
PART 13: Vendor landscape
‧ Competitive scenario
PART 14: Key vendor analysis
‧ Astellas Pharma
‧ Eli Lilly
‧ GlaxoSmithKline
‧ Sanofi
‧ Other prominent vendors
PART 15: Appendix
‧ List of abbreviations
List of Exhibits
Exhibit 01: Risk factors of prostate gland enlargement
Exhibit 02: Difference between prostate cancer and BPH
Exhibit 03: Pipeline analysis
Exhibit 04: Pipeline landscape
Exhibit 05: Global BPH drugs market snapshot
Exhibit 06: Global BPH drugs market 2016-2021 ($ millions)
Exhibit 07: Five forces analysis
Exhibit 08: Market segmentation by MOA 2016
Exhibit 09: Global BPH alpha-blockers drugs market 2016-2021 ($ millions)
Exhibit 10: Global BPH 5-ARIs drugs market 2016-2021 ($ millions)
Exhibit 11: Global BPH PDE-5 inhibitors drugs market 2016-2021 ($ millions)
Exhibit 12: Segmentation of global BPH drugs market based on geography 2016 and 2021 (%)
Exhibit 13: Global BPH drugs market revenue by geography 2016-2021 ($ millions)
Exhibit 14: Market scenario in Americas
Exhibit 15: BPH drugs market in Americas 2016-2021 ($ millions)
Exhibit 16: Market scenario in EMEA
Exhibit 17: BPH drugs market in EMEA 2016-2021 ($ millions)
Exhibit 18: Market scenario in APAC
Exhibit 19: BPH drugs market in APAC 2016-2021 ($ millions)
Exhibit 20: Percentage of potential population for BPH among people with 65+ years 2014 and 2050
Exhibit 21: Prominent side effects of BPH medication
Exhibit 22: Impact of patent loss on AVODART 2014-2015 (GBP millions)
Exhibit 23: New advancements in diagnosis of BPH
Exhibit 24: Competitive structure analysis of global BPH drugs market 2016
Exhibit 25: Competitive analysis of global BPH drugs market
Exhibit 26: Astellas Pharma: Strength assessment
Exhibit 27: Astellas Pharma: Strategy assessment
Exhibit 28: Astellas Pharma: Opportunity assessment
Exhibit 29: Eli Lilly: Key highlights
Exhibit 30: Eli Lilly: Strength assessment
Exhibit 31: Eli Lilly: Strategy assessment
Exhibit 32: Eli Lilly: Opportunity assessment
Exhibit 33: GlaxoSmithKline: Strength assessment
Exhibit 34: GlaxoSmithKline: Strategy assessment
Exhibit 35: GlaxoSmithKline: Opportunity assessment
Exhibit 36: Sanofi: Key highlights
Exhibit 37: Sanofi: Strength assessment
Exhibit 38: Sanofi: Strategy assessment
Exhibit 39: Sanofi: Opportunity assessment
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
‧ Market outline
PART 05: BPH diagnostics
‧ Overview
PART 06: Pipeline landscape
PART 07: Market landscape
‧ Market overview
‧ Five forces analysis
PART 08: Market segmentation by MOA
‧ Alpha-blockers
‧ 5-ARIs
‧ PDE-5 inhibitors
‧ Others
PART 09: Geographical segmentation
‧ BPH drugs market in Americas
‧ BPH drugs market in EMEA
‧ BPH drugs market in APAC
PART 10: Decision framework
PART 11: Drivers and challenges
‧ Market drivers
‧ Market challenges
PART 12: Market trends
‧ Advancements in early-stage diagnosis through new diagnostic methods
‧ Growing demand for MRI and ultrasound-guided prostate biopsy procedures
‧ Growing focus toward new MOA
PART 13: Vendor landscape
‧ Competitive scenario
PART 14: Key vendor analysis
‧ Astellas Pharma
‧ Eli Lilly
‧ GlaxoSmithKline
‧ Sanofi
‧ Other prominent vendors
PART 15: Appendix
‧ List of abbreviations
List of Exhibits
Exhibit 01: Risk factors of prostate gland enlargement
Exhibit 02: Difference between prostate cancer and BPH
Exhibit 03: Pipeline analysis
Exhibit 04: Pipeline landscape
Exhibit 05: Global BPH drugs market snapshot
Exhibit 06: Global BPH drugs market 2016-2021 ($ millions)
Exhibit 07: Five forces analysis
Exhibit 08: Market segmentation by MOA 2016
Exhibit 09: Global BPH alpha-blockers drugs market 2016-2021 ($ millions)
Exhibit 10: Global BPH 5-ARIs drugs market 2016-2021 ($ millions)
Exhibit 11: Global BPH PDE-5 inhibitors drugs market 2016-2021 ($ millions)
Exhibit 12: Segmentation of global BPH drugs market based on geography 2016 and 2021 (%)
Exhibit 13: Global BPH drugs market revenue by geography 2016-2021 ($ millions)
Exhibit 14: Market scenario in Americas
Exhibit 15: BPH drugs market in Americas 2016-2021 ($ millions)
Exhibit 16: Market scenario in EMEA
Exhibit 17: BPH drugs market in EMEA 2016-2021 ($ millions)
Exhibit 18: Market scenario in APAC
Exhibit 19: BPH drugs market in APAC 2016-2021 ($ millions)
Exhibit 20: Percentage of potential population for BPH among people with 65+ years 2014 and 2050
Exhibit 21: Prominent side effects of BPH medication
Exhibit 22: Impact of patent loss on AVODART 2014-2015 (GBP millions)
Exhibit 23: New advancements in diagnosis of BPH
Exhibit 24: Competitive structure analysis of global BPH drugs market 2016
Exhibit 25: Competitive analysis of global BPH drugs market
Exhibit 26: Astellas Pharma: Strength assessment
Exhibit 27: Astellas Pharma: Strategy assessment
Exhibit 28: Astellas Pharma: Opportunity assessment
Exhibit 29: Eli Lilly: Key highlights
Exhibit 30: Eli Lilly: Strength assessment
Exhibit 31: Eli Lilly: Strategy assessment
Exhibit 32: Eli Lilly: Opportunity assessment
Exhibit 33: GlaxoSmithKline: Strength assessment
Exhibit 34: GlaxoSmithKline: Strategy assessment
Exhibit 35: GlaxoSmithKline: Opportunity assessment
Exhibit 36: Sanofi: Key highlights
Exhibit 37: Sanofi: Strength assessment
Exhibit 38: Sanofi: Strategy assessment
Exhibit 39: Sanofi: Opportunity assessment
